Loading clinical trials...

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Study of Longitudinal Observation for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia in Collaboration With Asian Partners

An International, Multicenter, Prospective, Longitudinal Observational Study for Patient With X-linked Hypophosphatemic Rickets/Osteomalacia

NCT03745521•Kyowa Kirin Co., Ltd.

View on ClinicalTrials.gov

Summary

Through observation of patients with X-linked hypophosphatemic rickets/osteomalacia (XLH) for up to 10 years, the study intends to collect data that allow achievement of the following objectives: 1. To determine medical characteristics of the disease and the disease process 2. To determine physical and psychological burden on patients as well as economic burden 3. To assess the efficacy and safety of the treatment of the disease

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients must meet at least one of the following:
•1. Documented PHEX gene mutation
•2. Documented PHEX gene mutation in at least one family member with X-linked genetic relationship
•3. Documented FGF23 \>30 pg/mL
•Typical clinical findings of rickets/osteomalacia
•Written informed consent obtained from patients aged \>=18 years or from parents or legally acceptable representatives of patients aged \<18 years

Exclusion Criteria

•Participation in any clinical study (trial) at the time of informed consent
•Any patient whose participation in the study is considered inappropriate by the investigator or the subinvestigator

Locations (1)

Osaka University Hospital

Osaka, Japan

Key Dates

Start Date

May 1, 2018

Primary Completion Date

December 31, 2028

Completion Date

December 31, 2028

Last Updated

September 5, 2025

Enrollment

226

ACTUAL participants

Conditions

X-Linked Hypophosphatemia

Interventions

no intervention

OTHER

Expanded Access to Burosumab

NCT03775187

X-linked HypophosphatemiaTumor-Induced Osteomalacia

View study

COMPLETEDPHASE4

Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH

NCT04842032

X-linked Hypophosphatemia (XLH)

View study

COMPLETEDPHASE3

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions